IP Library Granted Patent US 8,552,145
Granted Patent B2
US 8,552,145 · App. 13/462,314 · Granted Oct 8, 2013

Vaccine for modulating between T1 and T2 immune responses

Inventors: Wladyslaw A. Budzynski (Edmonton, CA); R. Rao Koganty (Edmonton, CA); Mark J. Krantz (Edmonton, CA); B. Michael Longenecker (Edmonton, CA)
Assignee: Oncothyreon Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,552,145
App. No.
13/462,314
Granted
Oct 8, 2013
Kind
B2
Abstract

The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.

Claims (13)

1. A liposomal composition comprising a MUC1 dilipopeptide, said dilipopeptide comprising TSAPDTRPAPGS (amino acids 24-35 of SEQ ID NO:1), wherein two amino acids of said dilipopeptide are lipidated and wherein the dilipopeptide is (a) a dilipopeptide selected from the group consisting of BP1-265 (SEQ ID NO:14), BP1-271 (SEQ ID NO:15), BP1-273 (SEQ ID NO:17), BP1-274 (SEQ ID NO:18), and BP1-236 (SEQ ID NO:13), or (b) a dilipopeptide differing from (a) solely by the replacement of at least one lipid group with another lipid group.

2. The composition of claim 1 wherein the dilipopeptide differs from (a) solely by the replacement of at least one lipid group with another lipid group and in which each lipidated amino acid is lipidated with a lipid selected independently from the group consisting of myristyl, palmitoyl and lauryl.

3. The composition of claim 1 , which further comprises an adjuvant.

4. The composition of claim 3 , wherein the adjuvant is selected from the group consisting of lipid A or a derivative thereof, monophosphoryl lipid A, muramyl dipeptide, and IL-2.

5. The composition of claim 3 , wherein the adjuvant is lipid A or a derivative thereof or monophosphoryl lipid A.

6. The composition of claim 1 , wherein the dilipopeptide comprises one or more glycosylated amino acids.

7. The composition of claim 1 , wherein the dilipopeptide further comprises a MUC 1 carbohydrate linked to serine or threonine of said dilipopeptide.

8. The composition of claim 1 , wherein the dilipopeptide is BP1-265 (SEQ ID NO:14).

9. The composition of claim 1 , wherein the dilipopeptide is BP1-271 (SEQ ID NO:15).

10. The composition of claim 1 , wherein the dilipopeptide is BP1-273 (SEQ ID NO:17).

11. The composition of claim 1 , wherein the dilipopeptide is BP1-274 (SEQ ID NO:18).

12. The composition of claim 1 , wherein the dilipopeptide is BP1-236 (SEQ ID NO:13).

13. A liposomal composition comprising a MUC1 dilipopeptide, said dilipopeptide comprising TSAPDTRPAPGS (amino acids 24-35 of SEQ ID NO:1), wherein two amino acids of said dilipopeptide are lipidated and said dilipopeptide comprises BP1-265 (SEQ ID NO:14).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2012
From: BUDZYNSKI, WLADYSLAW A.; KOGANTY, R. RAO; KRANTZ, MARK J.; LONGNECKER, B. MICHAEL
To: BIOMIRA, INC.
Reel/Frame 028597/0934 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2012
From: ONCOTHYREON CANADA INC.
To: ONCOTHYREON INC.
Reel/Frame 028598/0360 →
MERGER Recorded Jul 20, 2012
From: BIOMIRA, INC.
To: ONCOTHYREON CANADA INC.
Reel/Frame 028608/0364 →
Continuity (3)
Continuation 10106876 · Mar 27, 2002
Provisional Application 60278698 · Mar 27, 2001
Related Publication 20120269884A1 · Oct 25, 2012